Thursday broker round-up UPDATE
25th Apr 2013 09:07
Barclays: Morgan Stanley lowers target price from 438p to 424p and reiterates an overweight rating. Bellzone Mining: Investec reduces target price from 21p to 5.28p and downgrades to hold. BG Group: Bank of America cuts target price from 1300p to 1250p retaining a neutral rating. Brown (N) Group:
Read moreHutchison China MediTech to partner with Nestle subsidiary in healthcare JV
12th Apr 2013 12:28
Nestlé Health Science SA, a fully-owned subsidiary of Nestlé SA, and Hutchison China MediTech have announced that all regulatory approvals required for the establishment of a 50/50 joint venture Nutrition Science Partners Limited have been received. Hutchison China MediTech said that the purpose o
Read moreThursday broker round-up UPDATE
29th Nov 2012 07:27
Aberdeen Asset Management: Morgan Stanley raises target price from 365p to 375p; keeping an overweight rating. ASOS: Societe Generale raises target price from 2500p to 2530p and reiterates its hold recommendation. Babcock International: UBS downgrades from buy to neutral. Barratt Developments: HS
Read moreHutchison initiates phase 1 on Theliatinib trial
1st Nov 2012 12:40
Pharmaceutical company Hutchison China MediTech (Chi-MEd) has announced that through its majority-owned research and development company it has initiated the first-in-human phase 1 clinical trial of its Theliatinib (HMPL-309) product. The firm said the main aim of the study is to evaluate its safe
Read moreHutchison China Meditech director tops up stake
13th Sep 2012 15:54
Michael Howell, an Independent Non-Executive Director at Hutchison China Meditech, a research and development company majority-owned by Chi-Med, purchased 31,800 shares at 435.00p each on Tuesday. The £138,330 transaction, which takes Howell's interest in the company to 153,600 shares, comes six we
Read moreChina market booming for Chi-Med
31st Jul 2012 10:41
Hutchison China MediTech (Chi-MEd) saw profits jump in the first half and said it was well-positioned to take advantage of the enormous Chinese market. The AIM-listed firm saw pre-tax profits almost double to $6.5m on revenues of $109.2m. The firm said profits had been spurred on by the rapid expa
Read moreWednesday broker round-up - UPDATE
22nd Feb 2012 09:32
Vodafone: Credit Suisse cuts target from 175p to 170p, outperform rating kept. Vedanta Resources: Credit Suisse maintains neutral rating and 1,400p target. AMEC: UBS raises target from 1,225p to 1,325p, buy rating unchanged; Nomura raises target from 1,130p to 1,240p, buy rating unchanged. HSBC:
Read moreThursday broker round-up - UPDATE
12th Jan 2012 09:08
Reckitt Benckiser: J.P. Morgan Cazenove downgrades to neutral from overweight. Tesco: Nomura reiterates buy rating and 500p target; Panmure Gordon cuts target from 500p to 440p, buy rating unchanged. Royal Bank of Scotland: Shore Capital reiterates sell. Tesco: Shore Capital downgrades to hold fr
Read moreLondon close: Footsie flounders at the finish
21st Dec 2011 16:40
It was a day of two halves for the Footsie, with the morning's gains reversed in the afternoon session in the wake of the result of the European Central Bank's new three-year credit facility. The European Central Bank allotted €489.2bn in its auction of three-year loans, whereas the market had been
Read moreLondon midday: Footsie laid low by Unicredit, rumours of French downgrade?
21st Dec 2011 11:39
The banks were providing a lift at midday, but the Footsie was registering only slight gains with only a few days before Christmas. Hopes of a 'Santa rally' seem to have been dampened towards midday by the suspension from trading of shares of Unicredit 'limit-down'. They have since resumed trading
Read moreLondon open: Wall Street tailwinds lift London
21st Dec 2011 08:34
Following last night's strong showing on Wall Street, UK shares are heading higher this morning, although in more leisurely fashion than their US counterparts did yesterday. Investors do not seem to be too fazed by credit ratings agency Moody's saying Britain's cherished triple-AAA credit rating co
Read moreAstraZeneca and Hutchison seal cancer drug deal
21st Dec 2011 07:42
FTSE 100 pharmaceuticals firm AstraZeneca and Hutchison MediPharma (HMP), a research and development company majority-owned by Chi-Med, have entered into a global licensing, co-development, and commercialisation agreement for a cancer treatment drug. Volitinib (also known as HMPL-504), which was d
Read moreSunday tips round-up: SSE, Afren, Diploma, Chi-Med
22nd May 2011 12:14
Utilities are traditionally favourite choices of cautious investors looking for income, and Scottish and Southern Energy (SSE) is no exception. Questor in the Sunday Telegraph notes the current prospective yield is 5.8%, rising to 6.1% next year. The company aims to make a full-year dividend incre
Read moreSmall caps round-up: Encore Oil, Chime Comms, Hutchison China...
9th Mar 2011 15:44
North Sea oil explorer Encore Oil is looking to float a new company made up of its exploration assets on AIM, while maintaining a "significant" shareholding. "The new company would raise the necessary capital to progress a high impact exploration drilling programme," it said alongside today's int
Read moreSmall caps round-up: Forte Energy, Discovery Metals Proximagen...
21st Dec 2010 09:59
Uranium company Forte Energy has been testing for rare earth elements (REE) in Guinea and the latest assay results indicate "provide a higher level of encouragement that a substantial body of REE mineralisation may exist within the company's 100% owned Firawa uranium project." "REE assays from thes
Read more